Search Results - "GRASELA, D. M"

Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections by AMBROSE, Paul G, GRASELA, Dennis M, GRASELA, Thaddeus H, PASSARELL, Julie, MAYER, Howard B, PIERCE, Phillip F

“…Fluoroquinolone antibiotic agents have demonstrated efficacy in the treatment of respiratory tract infections. This analysis was designed to examine the…”
Get full text

Multiple-Dose Safety and Pharmacokinetics of Oral Garenoxacin in Healthy Subjects by GAJJAR, D. A, BELLO, A, GE, Z, CHRISTOPHER, L, GRASELA, D. M

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Clinical Pharmacology of Gatifloxacin, a New Fluoroquinolone by GRASELA, Dennis M

“…Gatifloxacin is an advanced-generation, 8-methoxy fluoroquinolone that is active against a broad spectrum of pathogens, including antibiotic-resistant…”
Get full text

Pharmacometrics and the Transition to Model-Based Development by Grasela, T H, Dement, C W, Kolterman, O G, Fineman, M S, Grasela, D M, Honig, P, Antal, E J, Bjornsson, T D, Loh, E

“…As the transition to model‐based drug development continues, pharmacometric analysis will have an increasingly important role across the entire life cycle of…”
Get full text

The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae by Ambrose, Paul G., Grasela, Dennis M.

“…Background: For fluoroquinolones, AUC:MIC ratios correlate with maximal bacterial eradication in in vitro models of infection and favorable cure rates in…”
Get full text

Ecological impact of the des-F(6)-quinolone, BMS-284756, on the normal intestinal microflora by Nord, C.E., Gajjar, D.A., Grasela, D.M.

“…BMS-284756 (T-3811ME) is a novel des-F(6)-quinolone effective against a broad spectrum of aerobic and anaerobic pathogens. The aim of this study was to…”
Get full text

Pharmacokinetics and safety of a single dose of stavudine (d4T) in patients with severe hepatic impairment by SCHAAD, H. J, PETTY, B. G, GRASELA, D. M, CHRISTOFALO, B, RAYMOND, R, STEWART, M

“…Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon…”
Get full text

The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults by NOOR, Mustafa A, PARKER, Rex A, O'MARA, Edward, GRASELA, Dennis M, CURRIE, Alexander, HODDER, Sally L, FIEDOREK, Fred T, HAAS, David W

“…Therapy with some HIV protease inhibitors (PI) contributes to insulin resistance and type 2 diabetes mellitus, by inhibition of insulin-sensitive glucose…”
Get full text

Comparative Safety, Tolerance, and Pharmacokinetics of Amphotericin B Lipid Complex and Amphotericin B Desoxycholate in Healthy Male Volunteers by Kan, V. L., Bennett, J. E., Amantea, M. A., Smolskis, M. C., McManus, E., Grasela, D. M., Sherman, J. W.

“…Amphotericin B lipid complex (ABLC), a lipid complex formulation of amphotericin B, and amphotericin B desoxycholate (AB) were compared for safety, tolerance,…”
Get full text

Pharmacokinetics of Single-Dose Oral Stavudine in Subjects with Renal Impairment and in Subjects Requiring Hemodialysis by GRASELA, D. M, STOLTZ, R. R, BARRY, M, BONE, M, MANGOLD, B, O'GRADY, P, RAYMOND, R, HAWORTH, S. J

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Effect of Multiple-Dose Gatifloxacin or Ciprofloxacin on Glucose Homeostasis and Insulin Production in Patients with Noninsulin-Dependent Diabetes Mellitus Maintained with Diet and Exercise by Gajjar, Diptee A., LaCreta, Frank P., Kollia, Georgia D., Stolz, Randall R., Berger, Sheldon, Smith, William B., Swingle, Mary, Grasela, Dennis M.

“…Study Objectives. To compare the effects of gatifloxacin and ciprofloxacin on glucose homeostasis, including glucose tolerance test (GTT), pancreatic β‐cell…”
Get full text

A Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Gatifloxacin in Healthy Adult Men by Gajjar, Diptee A., LaCreta, Frank P., Uderman, Howard D., Kollia, Georgia D., Duncan, Glenn, Birkhofer, Martin J., Grasela, Dennis M.

“…Study Objectives. To examine single‐ and multiple‐dose safety, tolerability and pharmacokinetics of gatifloxacin administered as daily 1‐hour intravenous…”
Get full text

Open-Label, Nonrandomized Study of the Effects of Gatifloxacin on the Pharmacokinetics of Midazolam in Healthy Male Volunteers by Grasela, Dennis M., LaCreta, Frank P., Kollia, Georgia D., Randall, Diane M., Uderman, Howard D.

“…Study Objective. To confirm findings from an in vitro study that showed gatifloxacin did not substantially inhibit cytochrome P450 (CYP) 3A4 model substrate…”
Get full text

Effect of Garenoxacin on Eubacteria in the Normal Intestinal Microflora when Administered Concomitantly with Digoxin by Nord, C.E., Meurling, L., Russo, R.L., Bello, A., Grasela, D.M., Gajjar, D.A.

“…Garenoxacin is a new des-F(6-quinolone with a broad antimicrobial spectrum. It has been reported that antibiotics may raise digoxin concentrations in the…”
Get full text

Interchangeability of 400-mg Intravenous and Oral Gatifloxacin in Healthy Adults by LaCreta, Frank P., Kaul, Sanjeev, Kollia, Georgia D., Duncan, Glenn, Randall, Dianne M., Grasela, Dennis M.

“…Study Objective. To evaluate the interchangeability of 400‐mg intravenous and oral doses of gatifloxacin. Design. Randomized, open‐label, crossover study…”
Get full text

Age and Gender Effects on the Pharmacokinetics of Gatifloxacin by LaCreta, Frank P., Kollia, Georgia D., Duncan, Glenn, Behr, Douglas, Grasela, Dennis M.

“…Study Objective. To compare the pharmacokinetics and safety of gatifloxacin in elderly (≥ 65 yrs) and young (18–45 yrs) men and women. Design. Open‐label,…”
Get full text

Deoxyspergualin: mechanism of action and pharmacokinetics by Ramos, E L, Nadler, S G, Grasela, D M, Kelley, S L

Get more information

The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients by GEHR, T. W. B, SICA, D. A, GRASELA, D. M, DUCHIN, K. L

“…The pharmacokinetics and pharmacodynamics of fosinoprilat, the diacid of fosinopril sodium (a new angiotensin-converting enzyme (ACE) inhibitor), were…”
Get full text

Safety and Pharmacokinetics of a Single Oral Dose of Gatifloxacin in Patients with Moderate to Severe Hepatic Impairment by Grasela, Dennis M., Christofalo, Barbara, Kollia, Georgia D., Duncan, Glenn, Noveck, Robert, Manning Jr, James A., LaCreta, Frank P.

“…Study Objectives. To assess the safety and pharmacokinetics of oral gatifloxacin 400 mg in subjects with and without hepatic impairment, and the need to modify…”
Get full text

Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients by GEHR, T. W. B, SICA, D. A, GRASELA, D. M, FAKHRY, I, DAVIS, J, DUCHIN, K. L

“…The pharmacokinetics and pharmacodynamics of fosinoprilat, the diacid of fosinopril sodium, a new angiotensin-converting enzyme (ACE) inhibitor, were…”
Get full text